Oviva closes €200 million Series D for AI-supported healthcare

The Berlin-based digital health company Oviva has closed a Series D financing round of 200 million euros. The round consists of primary and secondary capital and is led by Kinnevik. Other investors include Planet First Partners, A.P. Moller Holding, Lunate, EGS Beteiligungen AG, Norrsken VC and existing investor Sofina.

Oviva is a European provider of digital, reimbursable therapies for obesity and chronic diseases. The financing is one of the largest growth rounds in the European digital health sector in recent years.

Expansion into other chronic indications planned

Oviva intends to use the fresh capital to expand its range of treatments beyond obesity. Plans include the expansion of digital therapy programs for high blood pressure and type 2 diabetes in order to prevent cost-intensive secondary diseases at an early stage or treat them more effectively.

At the same time, the company is investing in the further development of its AI-supported platform, which offers patients personalized treatment paths and supports healthcare professionals in their day-to-day treatment.

Digital care to combat a shortage of specialists and waiting times

In Europe, over 200 million adults live with obesity, while access to long-term care is limited. Healthcare systems are increasingly struggling with skills shortages and long waiting times.

By providing earlier support and ongoing patient care, we prevent the progression of chronic diseases.

Kai Eberhardt, CEO and co-founder of Oviva

Oviva says it is addressing this gap with certified digital therapy programs that are fully reimbursed by health insurance companies and public healthcare systems in Germany, Switzerland and the UK. This gives patients access to interdisciplinary care regardless of their location without having to wait months.

Particularly in the area of obesity therapies, we cannot necessarily understand this lack in the German healthcare system, at least for qualified approaches by members of the DEG and nutritionists. Nutritional counseling is still not a protected term and anything that goes beyond simple dietary assistance should always be done in agreement between nutritionists, doctors and health insurance companies. This is very important, if only to recognize therapy-induced deficiencies at an early stage and prevent them from developing in the first place.

Over one million patients treated and scientifically proven

Since its foundation in 2014, Oviva has treated more than one million patients. The effectiveness of the programs has been proven by over 90 peer-reviewed studies. In the past two years, the number of patients has tripled and the company achieved operational profitability in 2025.

The platform combines an app certified as a medical device with human support from interdisciplinary treatment teams. AI ensures scalability, quality assurance and efficiency.

Long-term investors with an impact focus

With Kinnevik and the co-investors involved, the round brings together long-term healthcare investors with a clear impact focus. The aim is to build a scalable supply infrastructure that will sustainably relieve the burden on Europe's healthcare systems.